



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>C07J 17/00, A61K 31/58</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/04365</b>  <b>(43) International Publication Date:</b> 19 March 1992 (19.03.92)
<b>(21) International Application Number:</b> PCT/US91/06249 <b>(22) International Filing Date:</b> 6 September 1991 (06.09.91) <b>(30) Priority data:</b> 580,239 10 September 1990 (10.09.90) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 580,239 (CIP) Filed on 10 September 1990 (10.09.90) <b>(71) Applicant (for all designated States except US):</b> SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> YUEN, Pui-Ho [US/US]; 1 Stanford Place, Princeton Junction, NJ 08550 (US). ECKHART, Charles [US/US]; 45 North 21st Street, Kenilworth, NJ 07039 (US). ETLINGER, Teresa [US/US]; 39 Elmbrook Place, Bloomfield, NJ 07003 (US). LEVINE, Nancy [US/US]; 12 Cider Mill Circle, Flemington, NJ 08822 (US).		<b>(74) Agents:</b> MAITNER, John, J. et al.; Schering-Plough Corporation, One Giralda Farms, Madison, NJ 07940-1000 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU*, TD (OAPI patent), TG (OAPI patent), US.  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> MOMETASONE FUROATE MONOHYDRATE, PROCESS FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS		
<b>(57) Abstract</b>  The invention relates to the novel compound mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing said compound.		

# + DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

5

**MOMETASONE FUROATE MONOHYDRATE. PROCESS  
FOR MAKING SAME AND PHARMACEUTICAL  
COMPOSITIONS**

10

**BACKGROUND OF THE INVENTION**

The present invention relates to a novel composition of matter,  $9\alpha,21$ -dichloro- $16\alpha$ -methyl- $1,4$ -pregnadiene- $11\beta,17\alpha$ -diol- $3,20$ -dione- $17-(2'$ -furoate) monohydrate, also designated mometasone furoate monohydrate, process for its preparation, and pharmaceutical preparation thereof.

Mometasone furoate is known to be useful in the treatment of inflammatory conditions. The compound is prepared by procedures disclosed in U.S. Patent No. 4,472,393, which patent is hereby incorporated by reference.


When aqueous pharmaceutical compositions, e.g. suspensions, containing anhydrous mometasone furoate were subjected to stability testing by rotating for four weeks at room temperature and  $35^{\circ}\text{C}$ , formation of a crystalline material which is different from the anhydrous mometasone furoate crystal was observed in suspension. Experiments were designed to determine the nature of the crystalline material. It was postulated that formulation of mometasone furoate compositions with the stable crystalline form would reduce the probability of crystal growth during long term storage of the suspension leading to a more stable product.

35

- 2 -

### SUMMARY OF THE INVENTION

The present invention provides mometasone furoate monohydrate of formula I



a process for preparing said compound by crystallization from a saturated aqueous water miscible organic solution. The present invention also provides aqueous stable pharmaceutical compositions of mometasone furoate monohydrate.

15

### DESCRIPTION OF THE FIGURES

Figure 1: Infrared spectrum of crystalline mometasone furoate monohydrate

20

Figure 2: X-ray diffraction pattern of crystalline mometasone furoate monohydrate

### DETAILED DESCRIPTION OF THE INVENTION

25

The composition of matter of the present invention, mometasone furoate monohydrate has the following characteristics.

30

- 3 -

	Molecular formula	$C_{27}H_{30}Cl_2O_6H_2O$
	Formula weight	539.46
	Elemental Analysis (theory)	C=60.11%, H=5.98%; Cl=13.16%
	(found)	C=59.99%; H=5.56%; Cl=13.17%
5	Water Analysis (% $H_2O$ ) (theory)	3.34%
	(found)	3.31, 3.47

The crystalline mometasone furoate monohydrate exhibits an x-ray crystallographic powder diffraction pattern having essentially the values as shown in Table I.

10

- 4 -

TABLE I

5	Angle of 2 $\theta$ (degrees)	Spacing d (Å)	Relative Intensity I/I
	7.795	11.3324	100
10	11.595	7.6256	6
	12.035	7.3478	3
	12.925	6.8437	11
	14.070	6.2893	22
	14.580	6.0704	5
15	14.985	5.9072	12
	15.225	5.8146	33
	15.635	5.6631	96
	16.710	5.3011	15
	17.515	5.0592	14
20	18.735	4.7324	12
	20.175	4.3978	13
	20.355	4.3593	6
	20.520	4.3246	4
	21.600	4.1108	5
25	21.985	4.0396	22
	22.420	3.9622	8
	22.895	3.8811	7
	23.245	3.8234	14
	23.550	3.7746	13
30	24.245	3.6680	4
	24.795	3.5878	11
	24.900	3.5729	5
	25.800	3.4503	5
	25.985	3.4262	3
35	26.775	3.3268	84
	27.170	3.2794	10
	27.305	3.2635	9

- 5 -

	Angle of 2 $\theta$ (degrees)	Spacing d (Å)	Relative Intensity I/I
5			
	27.710	3.2167	5
	28.385	3.1417	7
	29.165	3.0594	1
10	29.425	3.0330	2
	29.725	3.0030	2
	30.095	2.9670	7
	30.255	2.9516	3
	30.490	2.9294	10
15	30.725	2.9075	6
	31.115	2.8720	3
	31.595	2.8294	47
	32.135	2.7831	6
	32.985	2.7133	7
20	33.400	2.6805	2
	33.820	2.6482	2
	34.060	2.6301	8
	34.625	2.5885	4
	34.795	2.5762	2
25	35.315	2.5394	1
	36.780	2.4416	21
	37.295	2.4090	2

Single crystal data of mometasone furoate  
30 monohydrate exhibits the following values as shown in Table  
II.

- 6 -

TABLE II

Crystallographic Data<sup>a</sup>

5	Crystal system	triclinic
	Space group	$P1(C_1^1)$ - No. 1
	$a(\text{\AA})$	8.481(1)
	$b(\text{\AA})$	11.816(2)
10	$c(\text{\AA})$	7.323(1)
	$\alpha(^{\circ})$	95.00(1)
	$\beta(^{\circ})$	110.66(1)
	$\gamma(^{\circ})$	73.27(1)
	$V(\text{\AA}^3)$	657.5(3)
15	$D_{\text{calcd.}}(\text{g cm}^{-3})$	1.362

<sup>a</sup> An Enraf-Nonius CAD-4 diffractometer (Cu-K $\alpha$  radiation, incident-beam graphite monochromator) was used for all measurements. Intensity data were corrected for the usual Lorentz and polarization effects; an empirical absorption correction was also applied.

The crystal structure was solved by direct methods (RANTAN). Approximate non-hydrogen atom positions were derived from an  $E$ -map. Hydrogen atoms were located in a series of difference Fourier syntheses evaluated following several rounds of full-matrix least-squares adjustment of non-hydrogen atom positional and anisotropic temperature factor parameters. Hydrogen atom positional and isotropic thermal parameters were included as variables in the later least-squares iterations which also involved refinement of an extinction correction. Crystallographic calculations were performed on PDP11/44 and MicroVAX computers by use of the Enfra-Nonius Structure Determination Package (SDP). For all structure-factor calculations, neutral atom scattering factors

- 7 -

and their anomalous dispersion corrections were taken from International Tables for X-Ray Crystallography, vol. IV, The Kynock Press, Birmingham, England, 1974.

5 Mometasone furoate monohydrate can be prepared by forming a saturated homogeneous solution of anhydrous mometasone furoate in a mixture of water and a water miscible organic solvent. The saturated solution is prepared by dissolving the mometasone furoate in a water miscible organic solvent at the temperature of about 85°C. Hot water, 10 about 85°C, is added dropwise with agitation. After removing the solution from the steam bath, the reaction is stirred for about one hour and then allowed to stand undisturbed overnight while cooling to room temperature. The solution is stirred while adding additional water at room temperature 15 and the solution becomes cloudy and a white precipitate forms. The reaction is allowed to stir for a time, the precipitate collected by filtration and the product dried to constant weight.

Organic solvents that can be employed in the 20 process of this invention must be miscible with water and one in which mometasone furoate is soluble. Examples of water miscible organic solvents include alcohols, such as, ethanol, isopropanol, and the like; ketones, such as acetone, and the like; ethers, such as dioxane, and the like; esters such as ethyl 25 acetate, and the like. The preferred solvents are acetone and isopropanol.

In another aspect, the present invention provides pharmaceutical compositions comprising mometasone furoate monohydrate of formula I in an inert pharmaceutically 30 acceptable carrier or diluent.

The pharmaceutical compositions according to the invention can be prepared by combining mometasone furoate monohydrate with any suitable inert pharmaceutical carrier or

- 8 -

diluent and administered orally, parentally or topically in a variety of formulations.

Of particular interest are aqueous suspension compositions of mometasone furoate monohydrate, e.g. for nasal administration. The aqueous suspensions of the invention may contain from 0.1 to 10.0mg of mometasone furoate monohydrate per gram of suspension.

The aqueous suspension compositions according to the present invention may contain, inter alia, auxiliaries and/or more of the excipients, such as: suspending agents, e.g. microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropyl-methyl cellulose; humectants, e.g. glycerin and propylene glycol; acids, bases or buffer substances for adjusting the pH, e.g. citric acid, sodium citrate, phosphoric acid, sodium phosphate e.g. citrate and phosphate buffers; surfactants, e.g. Polysorbate 80; and antimicrobial preservatives, e.g. benzalkonium chloride, phenylethyl alcohol and potassium sorbate.

The following examples illustrate the present invention and the best made of practicing the process of the invention. It will be apparent to those skilled in the art that modifications thereof may be practical without departing from the purpose and intent of this disclosure.

#### General Experimental

Infrared absorption spectra were taken as Nujol Mull on a Nicolet FT-Infrared spectrometer Model No. 5DXB. X-ray crystallograph powder diffraction patterns were taken on a Philips X-ray diffractometer Model APD-3720 equipped with a radiation source: copper K $\alpha$ . Decomposition temperatures were measured on a Dupont differential scanning calorimeter, Model No. 990.

Moisture content of the crystalline mometasone furoate monohydrate was determined by titration with Karl Fisher reagent.

- 9 -

**EXAMPLE 1**

Place 4.5 liters of ethyl alcohol into a suitable vessel equipped with an appropriate agitator and closure.

- 5 Dissolve 27g of mometasone furoate anhydrous powder into the ethanol with stirring. Filter the saturated solution and slowly add purified water about 1.5 liters, at a flow rate of approximately 50 ml/minute while stirring at moderate speed. When the solvent mixture reaches a ratio of 1:3
- 10 (water:ethanol), the addition of water is stopped and stirring of the reaction mixture is continued for approximately 2 hours to facilitate seeding. Resume addition of water, about 7.5 liters at a rate of approximately 50 ml/minute, until a ratio of 2:1 (water:ethanol) is achieved. Continue stirring to complete
- 15 crystallization. The crystals are collected by filtration and dried in a vacuum desiccator at room temperature to afford 24.83g of mometasone furoate monohydrate having an infrared spectrum and X-ray diffraction graph substantially the same as that in Figures 1 and 2.

20

**EXAMPLE 2**

- Place 24.3 liters of 2-propanol into a suitable container. Dissolve 340 grams of anhydrous mometasone
- 25 furoate in the 2-propanol by heating the mixture (steam bath) to 85°C with stirring. After the furoate has dissolved, add dropwise with stirring over 15 minutes 1950 ml of hot (85°C) water. The hot solution is removed from the steam bath and the solution is stirred for 1 hour. The solution is allowed to
- 30 cool to room temperature overnight without stirring. The remainder of water, about 24 liters is added with stirring; the solution becomes cloudy and a white precipitate begins to form. The reaction is stirred for one hour, following addition of the water. The white precipitate is collected by filtration,

- 10 -

washed with 2 liters of water and air dried overnight. The solid is dried in a draft oven at 50°C to constant weight. Mometasone furoate monohydrate, 316.5g, weight yield 90%, is obtained having an infrared spectrum and X-ray diffraction graph substantially the same as that in Figures 1 and 2.

### EXAMPLE 3

An aqueous nasal suspension of mometasone furoate monohydrate is prepared from the following:

<u>Ingredients</u>	<u>Concentration</u> <u>mg/g</u>	<u>Representative Batch</u> <u>g/12kg</u>
Mometasone furoate monohydrate	0.5	6.0
Avicel RC 591*	20.0	240.0
Glycerin	21.0	252.0
Citric Acid	2.0	24.0
Sodium citrate	2.8	33.6
Polysorbate 80**	0.1	1.2
Benzalkonium chloride	0.2	2.4
Phenylethyl alcohol	2.5	30.0
Purified water q.s. ad	1.0 g	12.0 kg

\*Avicel RC-591-is a trademark of FMC for a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose.

\*\*Polysorbate 80 is a tradename for a mixture of an oleate ester of sorbitol and its anhydride copolymerized with approximately 20 moles of ethylene oxide for each mole of sorbitol and sorbitol anhydride.

After dispersing the Avicel RC 591 in 6 kg of purified water, the glycerin is added thereto. The citric acid

- 11 -

and sodium citrate is dissolved in 240 ml of water, said solution is added to the Avicel-glycerin dispersion with mixing. In a separate vessel, Polysorbate 80 is dissolved in approximately 400 ml of purified water with stirring. The

5 mometasone furoate monohydrate is dispersed in the aqueous Polysorbate 80 solution and; said slurry is then added with stirring to the Avicel-glycerin citric acid mixture. After dissolving benzalkonium chloride and phenylethyl alcohol in purified water, said solution is added to the suspension

10 mixture with stirring. The suspension is brought to 12 kg with purified water with mixing. The final pH of the suspension is  $4.5 \pm 0.5$ .

**EXAMPLE 4**

15

The following compositions were prepared without the suspending agent, Avicel RC-591 to prevent interference in X-ray diffraction studies:

<u>Ingredients</u>	<u>Concentration</u>		
	<u>mg/g</u>		
	<u>4A</u>	<u>4B</u>	<u>4C</u>
Mometasone Furoate	0.5	0.5	0.5
Monohydrate Micronized			
Citric Acid Monohydrate	2.0	2.0	2.0
Sodium Citrate Dihydrate	2.8	-	2.8
Sodium Phosphate Dibasic	-	4.0	-
Polysorbate 80	0.1	0.1	0.1
Benzalkonium Chloride	0.2	0.2	0.2
Phenylethyl Alcohol	2.5	-	-
Potassium Sorbate	-	3.4	-
Propylene Glycol	-	-	100.0
Glycerin	21.0	21.0	21.0
Water Purified USP q.s. ad	1.0 g	1.0 g	1.0 g

- 12 -

These compositions were prepared according to the procedure described in Example 3.

The three compositions 4A, 4B and 4C were  
5 rotated for five (5) days at 35°C and an additional four (4)  
weeks at room temperature to assess crystal form stability.  
The crystals were isolated from the suspension and X-ray  
diffraction patterns determined. The results indicated that  
the crystals collected from each of the three compositions  
10 are in the form of mometasone furoate monohydrate.

#### EXAMPLE 5

The following compositions were prepared and  
15 tested to determine thermal stability of said compositions.

<u>Ingredients</u>	<u>Concentration</u>		
	<u>mg/g</u>		
	<u>5A</u>	<u>5B</u>	<u>5C</u>
Mometasone Furoate	0.5	0.5	0.5
Monohydrate Micronized			
Citric Acid Monohydrate	2.0	2.0	2.0
Sodium Citrate Dihydrate	2.8	-	2.8
Sodium Phosphate Dibasic	-	4.0	-
Polysorbate 80	0.1	0.1	0.1
Benzalkonium Chloride	0.2	0.2	0.2
Phenylethyl Alcohol	-	2.5	-
Potassium Sorbate	-	-	3.4
Propylene Glycol	100.0	-	-
Glycerin	21.0	21.0	21.0
Avicel RC-591	20.0	20.0	20.0
Water Purified USP q.s. ad	1.0 g	1.0 g	1.0 g

- 13 -

The compositions were prepared according to the procedure described in Example 3.

5 The compositions were thermally cycled between 4°C (24 hours) and 30°C (24 hours) for a period of one month. Microscopic analyses revealed no detectable mometasone furoate monohydrate crystal growth under these conditions.

- 14 -

WE CLAIM:

1.  $9\alpha,21$ -dichloro- $16\alpha$ -methyl- $1,4$ -pregnadiene- $11\beta,17\alpha$ -diol- $3,20$ -dione- $17$ -( $2'$ -furoate) monohydrate.
- 5 2. A process for preparing  $9\alpha,21$ -dichloro- $16\alpha$ -methyl- $1,4$ -pregnadiene- $11\beta,17\alpha$ -diol- $3,20$ -dione- $17$ -( $2'$ -furoate) monohydrate which comprises:
  - 10 (a) forming a saturated water-miscible organic solvent solution of  $9\alpha,21$ -dichloro- $16\alpha$ -methyl- $1,4$ -pregnadiene- $11\beta,17\alpha$ -diol- $3,20$ -dione- $17$ -( $2'$ -furoate);
  - 15 (b) adding sufficient water to form a solvent mixture ratio of 1:1 (water:organic solvent) and continuing stirring to complete crystallization.
3. The process of claim 2 wherein the organic solvent  
20 is selected from the group consisting of ethanol, isopropanol, acetone, dioxane and ethyl acetate.
4. A pharmaceutical composition comprising an  
antiinflammatory amount of mometasone furoate monohydrate  
25 in a pharmaceutically acceptable carrier.


- 15 -

5. The composition of claim 4, having the following ingredients:

Ingredients	mg/g
Mometasone furoate monohydrate	0.1-10.0
Microcrystalline cellulose and sodium carboxymethyl cellulose	20.0
Glycerin	21.0
Citric acid	2.0
Sodium citrate	2.8
Polysorbate 80	0.1
Benzalkonium chloride	0.2
Phenylethyl alcohol	2.5
Purified water q.s. ad	1.0 g


6. The composition of claim 5 comprising 0.5mg of mometasone furoate monohydrate.

FIG. 1



SIRSTITUTE SHEET


FIG. 2



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/06249

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.C1.5                      C 07 J 17/00                      A 61 K 31/58		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.C1.5	C 07 J 17/00                      A 61 K 31/00	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	US,A,4775529 (J.A. SEQUEIRA) 4 October 1988, see the whole document ---	1-5
A	EP,A,0262681 (SCHERING CORP.) 6 April 1988, see the whole document -----	1-5
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search  <div style="text-align: center;">19-12-1991</div>		Date of Mailing of this International Search Report  <div style="text-align: center;">12. 02. 92</div>
International Searching Authority  <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>		Signature of Authorized Officer  <div style="text-align: center;">  </div>

# ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9106249

SA 51039

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 23/01/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4775529	04-10-88	AU-B- 616188	24-10-91
		AU-A- 1941788	21-12-88
		EP-A- 0292893	30-11-88
		EP-A- 0362270	11-04-90
		JP-T- 2501739	14-06-90
		WO-A- 8809174	01-12-88
EP-A- 0262681	06-04-88	US-A- 4808610	28-02-89
		AU-B- 603837	29-11-90
		AU-A- 8071287	21-04-88
		EP-A- 0318522	07-06-89
		JP-T- 2500976	05-04-90
		WO-A- 8802257	07-04-88